Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of SNDX 5613 (Revumenib) as Post-Transplant Maintenance After Allogeneic Hematopoietic Cell Transplant in Patients With KMT2A-Rearranged or NPM1-Mutated Acute Leukemia

NCT06575296 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06575296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06575296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of SNDX 5613 (Revumenib) as Post-Transplant Maintenance After Allogeneic Hematopoietic Cell Transplant in Patients With KMT2A-Rearranged or NPM1-Mutated Acute Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
December 6, 2024
Completion date
April 29, 2028
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, acute myeloid leukemia, childhood acute leukemia, childhood acute leukemia of ambiguous lineage, childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia